Literature DB >> 9401075

Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies.

V Snell1, K Clodi, S Zhao, R Goodwin, E K Thomas, S W Morris, M E Kadin, F Cabanillas, M Andreeff, A Younes.   

Abstract

T-cell cytotoxicity is primarily mediated by two cell surface proteins, Fas ligand (FasL) and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), and intracellular perforin and granzyme granules. FasL-deficient and perforin-deficient T lymphocytes maintain cytotoxicity but fail to induce graft-versus-host disease (GVHD) when transplanted into mice. suggesting that GVHD and graft-versus-tumour (GVT) effects can be dissociated, and that TRAIL is not involved in the pathogenesis of GVHD. Because TRAIL could mediate a favourable GVT effect it became important to study the spectrum of its activity and to investigate factors that can dissociate its expression from FasL. TRAIL induced apoptosis in 11/41 (27%) tumour specimens of haematological origin compared to 16/41 (39%) induced by FasL. Although eight specimens were sensitive to both FasL and TRAIL, no synergism was observed between these two ligands. TRAIL induced apoptosis in a dose and time dependent manner with an ED50 of 0.5 microg/ml and EDmax of 1 microg/ml. TRAIL activity was not reduced by the over-expression of the multidrug resistant (MDR) protein, and was not enhanced by 9-cis retinoic acid (RA), which can down-regulate bcl-2 protein. Both ligands were simultaneously up-regulated in normal peripheral blood lymphocytes in response to IL-2, IL-15 and anti-CD3 antibody, whereas IL-10 had no effect. Together, our data show that (1) TRAIL can mediate cell death in a variety of human haematological malignancies, (2) resistance to TRAIL is not mediated by MDR protein, (3) the lack of synergy between TRAIL and FasL suggests that either one is sufficient to mediate T-cell cytotoxicity, and (4) within the panel of cytokines tested, the expression of TRAIL and FasL could not be dissociated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9401075     DOI: 10.1046/j.1365-2141.1997.4393250.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

Review 1.  TNF-related apoptosis-inducing ligand (TRAIL) in rheumatoid arthritis: what's new?

Authors:  Anna Neve; Addolorata Corrado; Francesco Paolo Cantatore
Journal:  Clin Exp Med       Date:  2012-12-30       Impact factor: 3.984

2.  IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.

Authors:  T Teshima; G R Hill; L Pan; Y S Brinson; M R van den Brink; K R Cooke; J L Ferrara
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

3.  Killing effect of TNF-related apoptosis inducing ligand regulated by tetracycline on gastric cancer cell line NCI-N87.

Authors:  X C Wei; X J Wang; K Chen; L Zhang; Y Liang; X L Lin
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

Review 4.  The promise of TRAIL--potential and risks of a novel anticancer therapy.

Authors:  Ronald Koschny; Henning Walczak; Tom M Ganten
Journal:  J Mol Med (Berl)       Date:  2007-04-17       Impact factor: 4.599

5.  Safety and antitumor activity of recombinant soluble Apo2 ligand.

Authors:  A Ashkenazi; R C Pai; S Fong; S Leung; D A Lawrence; S A Marsters; C Blackie; L Chang; A E McMurtrey; A Hebert; L DeForge; I L Koumenis; D Lewis; L Harris; J Bussiere; H Koeppen; Z Shahrokh; R H Schwall
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

Review 6.  Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.

Authors:  Michelle A Fanale; Anas Younes
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 7.  Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis.

Authors:  F Morceau; M Dicato; M Diederich
Journal:  Mediators Inflamm       Date:  2010-03-01       Impact factor: 4.711

8.  A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma.

Authors:  A Younes; J M Vose; A D Zelenetz; M R Smith; H A Burris; S M Ansell; J Klein; W Halpern; R Miceli; E Kumm; N L Fox; M S Czuczman
Journal:  Br J Cancer       Date:  2010-11-16       Impact factor: 7.640

9.  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis.

Authors:  M J Smyth; E Cretney; K Takeda; R H Wiltrout; L M Sedger; N Kayagaki; H Yagita; K Okumura
Journal:  J Exp Med       Date:  2001-03-19       Impact factor: 14.307

10.  Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist.

Authors:  Chiara Boccellato; Emily Kolbe; Nathalie Peters; Viktorija Juric; Gavin Fullstone; Maïté Verreault; Ahmed Idbaih; Martine L M Lamfers; Brona M Murphy; Markus Rehm
Journal:  Cell Death Dis       Date:  2021-06-24       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.